Omalizumab, a monoclonal anti-IgE antibody, is currently FDA-approved for chronic spontaneous urticaria (CSU) in patients over 12 years old but is not indicated for acute urticaria. The gene discussed is IGHE; the disease is chronic idiopathic urticaria.